LENZ Therapeutics
LENZ
166 hedge funds and large institutions have $1.36B invested in LENZ Therapeutics in 2025 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 65 increasing their positions, 22 reducing their positions, and 4 closing their positions.
1,325% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 4
195% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 22
87% more capital invested
Capital invested by funds: $725M → $1.36B (+$630M)
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
47% more funds holding
Funds holding: 113 → 166 (+53)
14.32% more ownership
Funds ownership: 87.85% → 102.17% (+14%)
70% less call options, than puts
Call options by funds: $1.96M | Put options by funds: $6.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$97.7M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$25.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$21.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$14.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$28.6M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$23.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.2M |
| 4 |
Morgan Stanley
New York
|
-$10.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.2M |
LENZ Hedge Fund Activity: Q3 2025 in Review
166 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2025, worth a combined $1.36B — up 87% from $725M a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new LENZ positions and 4 closed out — a net gain of 53 holders — while 65 added to existing stakes and 22 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $97.7M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $28.6M sold.
- 166 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2025, up from 113 in Q2 2025.
- Funds reported $1.36B of LENZ Therapeutics stock for Q3 2025, up 87% quarter-over-quarter.
- 57 funds opened new LENZ Therapeutics positions in Q3 2025 and 4 closed out, a net change of +53 holders.
- The largest LENZ Therapeutics buyer in Q3 2025 was Versant Venture Management, an estimated $97.7M added.
- The largest LENZ Therapeutics seller in Q3 2025 was Sectoral Asset Management, an estimated $28.6M sold.
Based on aggregated 13F filings for Q3 2025.